NPPA Fixes Retail Price of Windlas Biotech, Biological E Paracetamol Combination Suspension

Susmita Roy

NPPA Fixes Retail Price of Windlas Biotech, Biological E Paracetamol Combination Suspension

Written By : Susmita Roy Published On 2026-08-29T19:30:57+05:30 | Updated On 29 Aug 2026 7:30 PM IST

New Delhi: Acting on the directions issued by the Department of Pharmaceuticals (DoP) in a review proceeding, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of a combination suspension containing Paracetamol, Phenylephrine Hydrochloride, Chlorpheniramine Maleate, Ammonium Chloride, Sodium Citrate and Menthol at Rs 0.70 per mL, exclusive of applicable Goods and Services Tax (GST).

The revised price applies to the formulation manufactured by Windlas Biotech Limited and marketed by Biological E. Limited.

The price fixation was notified through Order S.O. 4780(E), dated August 27, 2026, issued by the NPPA under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. The order was published in the Gazette of India, Extraordinary, on August 27, 2026.

The NPPA issued the order to implement the directions contained in the DoP review order bearing number 31015/06/2025-Pricing (E-36772), dated May 21, 2026, passed under paragraph 31 of the Drugs (Prices Control) Order, 2013. The authority exercised the powers conferred upon it under paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E), dated May 30, 2013, and S.O. 5249(E), dated November 11, 2022.

Also Read:Delhi HC Stays NPPA Notice Against AstraZeneca Over Alleged Betaloc-50 Overcharging

Through the latest order, the NPPA has superseded the earlier price order S.O. 3563(E), dated August 1, 2025, under which the formulation appeared at serial number 36. However, the supersession will not affect anything already done or omitted to be done before the issuance of the latest notification.

The formulation is a multi-ingredient suspension intended to combine antipyretic, decongestant, antihistaminic, expectorant and soothing agents. Each 5 mL, or one teaspoonful, contains Paracetamol IP 250 mg, Phenylephrine Hydrochloride IP 5 mg, Chlorpheniramine Maleate IP 2 mg, Ammonium Chloride IP 120 mg, Sodium Citrate IP 60 mg and Menthol IP 1 mg.

The notice stated,

"In implementation of directions of review order issued by the Department of Pharmaceuticals (DoP) under para 31 of Drugs (Prices Control) Order, 2013 vide order specified in column (7) of the table below and in exercise of the powers conferred by paragraphs 5,11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority), S.O. No. and date specified in the Column (7) of the table, the National Pharmaceutical Pricing Authority has fixed the price as specified in column (5) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (8) thereof."

S. No.	Name of formulation	Dosage form and strength	Unit	Retail price (Rs.)	DoP review order number and date	Existing S.O. number and date	Manufacturer and marketing company
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
1	Paracetamol, Phenylephrine HCl, Chlorpheniramine Maleate, Ammonium Chloride, Sodium Citrate and Menthol suspension	Each 5 mL (one teaspoonful) contains: Paracetamol IP 250 mg; Phenylephrine Hydrochloride IP 5 mg; Chlorpheniramine Maleate IP 2 mg; Ammonium Chloride IP 120 mg; Sodium Citrate IP 60 mg; and Menthol IP 1 mg	1 mL	0.70	31015/06/2025-Pricing (E-36772), dated 21.05.2026	S.O. 3563(E), dated 01.08.2025, at Sl. No. 36	M/s Windlas Biotech Limited / M/s Biological E. Limited

The notification further added,

(a) The manufacturer as specified in column (8), of the above mentioned formulations i.e. “new drug” under paragraph 2(1)(u) of the DPCO, 2013 may revise the retail price as specified in column (5) of the table hereinabove.

(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (5) of the above said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(e) The above mentioned retail prices are applicable only to the manufacturer / marketer as mentioned above for generic / any brand of the same composition / strength of the subject formulations, subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column(3) & (8) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (8) thereof, if any, issued prior to this notification, stand(s) superseded.

Also Read:NPPA Slaps Rs 79.97 Lakh Notice on AstraZeneca for Alleged Betaloc-50 Overcharging

To view the official notice, click the link below:

https://medicaldialogues.in/pdf_upload/2026/08/29/review-dop-27-08-2026-430208.pdf

nppaparacetamolPhenylephrine HCLchlorpheniramine maleateAmmonium Chloridementholwindlas biotechbiological eretail priceprice fixation

Susmita Roy

Mpharm (Pharmacology)

Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

Print Article